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Sexual Preoccupation & 
Hypersexuality
“an abnormally intense interest in sex that dominates psychological functioning” 
(Mann, Hanson & Thornton, 2010 pg. 198)
Terms used include:
• Sexual addiction (Marshall, Marshall, Moulden & Serran, 2008), 
• Hypersexual disorder (Krueger & Kaplan, 2002)
• Hypersexuality (Kaplan & Krueger, 2010)
Sex addiction is defined as: “a sexual desire disorder characterized by an 
increased frequency and intensity of sexually motivated fantasies, 
arousal, urges, and enacted behavior in association with an 
impulsivity component – a maladaptive behavioral response with 
adverse consequences” (Kafka, 2010, p. 385).
These terms are not used in order to negate responsibility, however they are 
helpful when thinking about treatment
Prevalence in the community
• Discrepancies in the literature between the terms mean 
prevalence rates differ; some reasonable estimates are:
o 3.0% for men and 1.2% for women on scores of compulsive 
sexual behaviour (used interchangeably with hypersexuality 
and sexual addiction; Odlaug et al., 2013)
o 3.1% of women who responded to an online survey were 
characterised as hypersexual (Klein, Rettenberger & Briken, 
2014; Reid, Garos & Carpenter, 2011)
• More recent research has revealed this figure to be increasing: 12.1% of a 
community male sample (n=8,718) had a TSO of at least 7 (Klein, Schmidt, 
Turner & Briken, 2015). 
• Positive correlational links found between pornography consumption and 
sexual compulsion and hypersexuality in women (Cates, 2015) – and 
promiscuity and excessive masturbation (impersonal not passive sex)
Current management and treatment of 
hypersexuality
• Rule out medical causes
• Consider medication to manage sexual arousal – together with 
therapy / psych treatment
Treated with 2 categories of medication: hormonal and non-hormonal 
medications medications
Hormonal drug therapy includes anti-androgens (for example, cyproterone 
acetate) and gonadotropin-releasing hormone (GnRH) analogues (for 
example, triptorelin). Cyproterone acetate (Androcur) is licensed for the 
control of libido in severe hypersexuality or sexual deviation in adult men. 
Triptorelin (Salvacyl) is licensed for the reversible reduction of testosterone 
to castrate levels in order to decrease sexual drive in adult men with severe 
sexual deviations.
Non-hormonal drug therapy includes antipsychotics (off-label use) and 
selective serotonin reuptake inhibitors (off-label use) (Khan et al. 2015).  
(From NICE, 2017)
Effectiveness assessed in a prison 
setting
• Hypersexuality/SP is an enduring psychological risk factor or long 
term vulnerability for sexual offending (Thornton & Knight, 2015) 
• Sexual preoccupation is a significant predictor for sexual, violent 
and general recidivism (Hanson & Morton-Bourgon, 2004; Hanson, 
Harris, Scott & Helmus, 2007)
• Results are typically higher in sexual offender populations, with 
findings suggesting 44% of incarcerated sexual offenders were 
considered as hypersexual compared to 18% of a matched 
community sample (Marshall & Marshall, 2006; Marshall, Marshall, 
Moulden, & Serran, 2008; Marshall, O’Brien, & Kingston, 2009).
Research Context
HMP Whatton, a treatment prison in the UK, holds 
approximately 840 adult males convicted of a sexual offence 
42% have a sentence of more than four years
56% are serving an indeterminate sentence including life 
sentence
Medication
Prescription guidelines from Professor Grubin 
oFluoxetine, Paroxetine (SSRIs)
oCyproterone acetate (CPA, anti androgen)
oTriptorelin (GnRH agonist)
•See Winder et al. (2014; 2017)  for evaluation
Evaluation
145 + adult men referred for medication; initial medication was:
• SSRIs 84
• AAs 18
• F/A 7
• GNRH 2
• under assessment 12
• NONE 22 (not suitable, not motivated, moving on)
Demographics
•Mean IQ (assessed by WASI or, where available WAIS) = 87.07  (sd = 16.15; 
58-118) 35 less than 80
•Mean age = 46.29 (sd = 14.60; 22-83) 
•Mean age at first conviction = 21.54 (sd = 9.49)
•Nationality: Majority British (reflecting ‘norm’ popn)
•History of abuse: Yes, typically - bullying, s/p abuse
Evaluation
Risk
Static risk (Risk Matrix 2000) scores:  
•Mean score for sexual risk = 2.9 (mode = 3, High)
– 36.36 % high 
– 30% very high
•Mean score for violence risk = 2.08 (mode = 1)
• Dynamic risk - Structured Assessment of Risk and Need (SARN)
o Typically scored highly on:
– Sexual preoccupation
– Inadequacy
– Poor problem solving
– Child abuse supportive beliefs
– Lack of emotionally intimate relationships
Clinical Measures
•Captured at regular meetings between participants and Dr Kaul (prescribing psychiatrist)
•Data collated during private therapeutic session; used clinically to discuss and tailor 
medication
Psychometric measures
Dynamic measures (baseline pre-meds, then approximately every 3 months)
• Sexual Compulsivity Scale (SCS)
o 10 items; 1-4; used means i.e. between 1-4; ‘My desires to have sex have 
disrupted my daily life’
• Hospital Anxiety and Depression Scale (HADS)
o Scoring is 0-21 on each sub-scale; caseness 8/21
• Severity Indices of Personality Problems (SIPP 118)
Static measures (conducted once only)
• PAI: Personality Assessment Inventory
o 22 scales measuring clinical, treatment and interpersonal factors related to 
personality
• MPI: My Private Interests
o Short scale measuring offence related sexual interests with 4 subscales 1) 
an obsession with sex; 2) a sexual interest in children; 3) a sexual interest in 
violent sex; and 4) multiple paraphilia.
Measures
Evidence base in prison –HMP 
Whatton
Figure 1: Mean Sexual Compulsivity Scores for participants taking 
medication to reduce sexual preoccupation: pre-medication, three 
months post-medication, and six months post-medication.
Sexual Compulsivity                                  
MMSA group have 
significantly higher 
Sexual Compulsivity
SC of main 
sex offender 
population at 
Whatton
Young 
sexually 
active 
students
Evidence base in prison 
Figure 3 
(left): 
Amount of 
time 
currently 
spent 
thinking 
about sex 
for 
participants 
taking (i) 
SSRIs and 
(ii) A-As
Figure 4 (left): 
Ability to distract 
from sexual 
thoughts for 
participants 
taking (i) SSRIs 
and (ii) A-As
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Psychometric Measures (dynamic)
Table 1: Means (SD) for HADS and Sexual Compulsivity scale 
Baseline T3 T6
Depression 6.74 (3.91) 4.29 (3.19) 3.82 (3.19)
Anxiety 10.36 (4.31) 6.71 (3.85) 5.89 (3.78)
Sexual 
Compulsivity
2.59 (0.75) 1.45 (0.50) 1.31 (0.39)
Psychometric Measures (dynamic)
 Prior to starting medication the research sample more closely resembled 
the clinical population (admissions to mental health institutes) than the 
general population on the SIPP-118. 
 The facets most problematic were effortful control, self-reflexive 
functioning, frustration tolerance, emotional regulation and stable self 
image.
 Both statistical and clinically significant change was observed in adaptive 
personality functioning on all scales by six months post medication. The 
percentage of reliable change of adaptive personality functioning was 
between 13.6% and 38.8%, moving functioning from the maladaptive 
range to the clinically ‘normal’ range (general population norms). 
 The majority of participants had moved into the healthy range of 
personality functioning within six months of taking medication.
BASELINE
SIPP scores VS general population, in-patients, out patients 
SIPP-118 Subscale
(Lower means 
more 
disordered) 
Participants 
(n=69)
General population 
(Andrea, 2007) 
(n=555)
In-patients 
(Andrea, 2007) 
(n=555)
Out patients 
(Andrea, 2007)  
(n=157)
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Emotional regulation 2.40 (0.67) 3.30 (0.61) p=.001 2.44 (0.69) ns 2.78 (0.63) p=.001
Effortful control 2.21 (0.66) 3.16 (0.56)  p=.001 2.53 (0.70)  p=.001 2.80 (0.71) p=.001
Frustration tolerance 2.38 (0.60) 2.96 (0.56)  p=.001 2.24 (0.56)  ns 2.36 (0.56)  ns
Responsible industry 2.72 (0.69) 3.44 (0.50)  p=.001 2.87 (0.67)  ns 3.07 (0.69)  p=.001
Aggression regulation 3.05 (0.82) 3.66 (0.45)  p=.001 3.30 (0.73)  p=.013 3.34 (0.66) p=.004
Intimacy 2.46 (0.56) 3.17 (0.60)  p=.001 2.68 (0.69)  p=.001 2.76 (0.63)  p=.001
Enduring relationships 2.53 (0.58) 3.31 (0.58)  p=.001 2.47 (0.67) ns 2.54 (0.65) ns
Self-respect 2.59 (0.73) 3.30 (0.59)  p=.001 2.36 (0.67) p=.01 2.35 (0.74) p=.008
CHANGES OVER TIME
SIPP scores of participants VS general population
SIPP-118 Subscale
(Lower means more 
disordered) 
General pop’n 
(n=478)
Participants 
Baseline  (n=69)
Participants 
3 months (n=54)
Participants 
6 months  (n=41)
Mean (SD) Mean (SD) T test 
p value
Mean (SD) T test 
p value
Mean (SD) T test 
p value
Emotional regulation 3.30 (0.61) 2.40 (0.67) p=.001
2.78 
(0.68)
p=.004
2.99 
(0.65)
p=.013
Effortful control 3.16 (0.56) 2.21 (0.66) p=.001
2.64 
(0.65)
p=.001
2.77 
(0.70)
p=.001
Frustration tolerance 2.96 (0.56) 2.38 (0.60) p=.001
2.76 
(0.64)
ns
2.86 
(0.59)
ns 
Responsible industry 3.44 (0.50) 2.72 (0.69) p=.001
2.96 
(0.60)
p=.001
3.13 
(0.56)
p=.001
Aggression regulation 3.66 (0.45) 3.05 (0.82) p=.001
3.25 
(0.69)
p=.007
3.38 
(0.62)
ns 
Intimacy 3.17 (0.60) 2.46 (0.56) p=.001
2.67 
(0.56)
p=.001
2.79 
(0.54)
p=.001
Enduring relationships 3.31 (0.58) 2.53 (0.58) p=.001
2.78 
(0.64)
p=.001
2.86 
(0.61)
p=.001
Self-respect 3.30 (0.59) 2.59 (0.73) p=.001
2.87 
(0.70)
p=.001
3.15 
(0.63)
ns
Conclusions
• Promising reductions in measures of clinical measures for 
individuals taking the medication (both types)
• Complementary to psychological treatment, not a 
replacement 
• Provides some support for the notion that personality, and in 
particular, self-control, are key mechanisms underlying 
hypersexuality and that the improved management of this 
could result in improved management of sexual thoughts.
• Hypersexuality may be one psychological and behavioural 
manifestation of maladaptive self-control,  presenting as an 
inability to manage urges, obsessional sexual thoughts, and 
poor coping (in the form of depression and anxiety). 
Service user reports: effects of 
medication
• Sexual preoccupation and associated  sexual behaviour
o Decreased frequency & intensity of sexual thoughts, fantasies 
and urges
o Reduction in masturbatory frequency
o Increased control of sexual thoughts  & ability to distract 
o Physical effects
• Obsessive compulsive disorder and depressive symptoms 
o Reduction in symptoms
o Increased ability to communicate with others and to socialise 
• Impulse and emotional control
o Increased ability to recognise inappropriate sexual thoughts
o Altered nature of fantasies
o Improved management of emotions.
• Side effects
o Tiredness, drowsiness, nausea, constipation and headaches
Reasons for stopping the medication
• Prior to commencing medication the main 
reasons for not taking MMSA include:
o Psychiatrist thinks its not needed 
o Refusal/participant feels sexual thoughts not an issue 
o Anxious about the side effects
o Other medical issues that need sorting before meds 
• Main reasons for discharges from service are 
release or transfer (often to another MMSA 
site).
• Other reasons include:
o Participant stopped collecting or taking meds 
o Participant feels better/no longer feels they need meds/in line 
with psychiatrist views
National Evaluation
• Ethical approval obtained:
o North Sea Camp (2 referrals and 2 research 
participants)
o HMP Hull (0 referrals)
• Awaiting NHS ethical approval:
o HMP USK
o HMP Isle of Wight
o HMP Leyhill
o HMP Frankland
Links
• Safer Living Foundation http://saferlivingfoundation.org/
• Lucy Faithfull Foundation  http://www.lucyfaithfull.org.uk/
• Stop It Now http://www.stopitnow.org.uk/
• Online help for people concerned about accessing images http://get-
help.stopitnow.org.uk/
• Support groups such as Sex Addicts Anonymous 
http://saauk.info/en/
• NICE guidelines : 
• https://www.nice.org.uk/advice/esuom46/chapter/full-evidence-
summary#introduction-and-current-guidance-2
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Additional slides
From here on – to expand on any points raised and 
possible qs
Testosterone levels
• 12 participants on Androcur with pre and post tests
• Serum testosterone levels nmol/L
• Androcur significantly reduces Testosterone levels 
p=0.0002
• Pre treatment levels slightly higher than norm
Key features Key findings
Service 
user 
studies
Aim: To explore the use of anti-libidinals 
to reduce sexual preoccupation and/or 
hypersexuality in convicted sexual 
offenders
Participants: 19 adult male sex offenders
Medication: Anti-androgens, SSRIs or 
combined
Analysis: Thematic analysis
• Reduced sexual preoccupation & 
arousal
• Improved impulse & emotional 
control
• Some noncompliance 
• No prior knowledge of medication
• Concerns about effects & long term 
use
Therapist 
study
Aim: To explore the experiences of 
individuals involved in the referral of 
pharmacological treatment and those who 
work with sexual offenders receiving 
pharmacological treatment
Participants: 8 intervention staff
Analysis: Thematic analysis
• Offenders’ concerns & insight
• Lack of feedback
• Lack of awareness about treatment 
& lack of support
• Concerns about throughcare
Offender 
supervisor 
study
Aim: To explore the perspectives and 
experiences of offender supervisors in 
relation to the pharmacological treatment
Participants: 6 offender supervisors 
Analysis: Thematic analysis
• Offenders’ reluctance to engage
• Lack of feedback 
• Lack of awareness
• Excluded from treatment process
• Importance of throughcare
Prescribing guidance: Prescribing 
unlicensed medicines
67. The term ‘unlicensed medicine’ is used to describe medicines that are used outside the terms of their UK licence or 
which have no licence for use in the UK.22 Unlicensed medicines are commonly used in some areas of medicine such as in 
paediatrics, psychiatry and palliative care. They are also used, less frequently, in other areas of medicine.
68. You should usually prescribe licensed medicines in accordance with the terms of their licence. However, you may 
prescribe unlicensed medicines where, on the basis of an assessment of the individual patient, you conclude, for medical 
reasons, that it is necessary to do so to meet the specific needs of the patient.
69. Prescribing unlicensed medicines may be necessary where:
a. There is no suitably licensed medicine that will meet the patient’s need. Examples include (but are not limited to), for 
example, where :23
i. there is no licensed medicine applicable to the particular patient. For example, if the patient is a child and a medicine 
licensed only for adult patients would meet the needs of the child; or
ii. a medicine licensed to treat a condition or symptom in children would nonetheless not meet the specific assessed needs 
of the particular child patient, but a medicine licensed for the same condition or symptom in adults would do so; or
iii. the dosage specified for a licensed medicine would not meet the patient’s need; or
iv. the patient needs a medicine in a formulation that is not specified in an applicable licence.
b. Or where a suitably licensed medicine that would meet the patient’s need is not available. This may arise where, for 
example, there is a temporary shortage in supply; or
c. The prescribing forms part of a properly approved research project.
70. When prescribing an unlicensed medicine you must:
a. be satisfied that there is sufficient evidence or experience of using the medicine to demonstrate its safety and efficacy
b. take responsibility for prescribing the medicine and for overseeing the patient’s care, monitoring, and any follow up 
treatment, or ensure that arrangements are made for another suitable doctor to do so
c. make a clear, accurate and legible record of all medicines prescribed and, where you are not following common practice, 
your reasons for prescribing an unlicensed medicine.
Prescribing guidance: Prescribing 
unlicensed medicines
Information for patients about the licence for their medicines.
71. You must give patients (or their parents or carers) sufficient information about the medicines you propose 
to prescribe to allow them to make an informed decision.
72. Some medicines are routinely used outside the terms of their licence, for example in treating children. In 
emergencies or where there is no realistic alternative treatment and such information is likely to cause 
distress, it may not be practical or necessary to draw attention to the licence. In other cases, where 
prescribing unlicensed medicines is supported by authoritative clinical guidance, it may be sufficient to 
describe in general terms why the medicine is not licensed for the proposed use or patient population.24 You 
must always answer questions from patients (or their parents or carers) about medicines fully and honestly.
73. If you intend to prescribe unlicensed medicines where that is not routine or if there are suitably licensed 
alternatives available, you should explain this to the patient, and your reasons for doing so.
74. You should be careful about using medical devices for purposes for which they were not intended.
